Anticancer Bioscience
Business Services · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Jingxing Road Biotown 30°25'49.8"n 103°5...Phone Number
+44 7968726585Website
www.anticancerbio.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Anticancer Bioscience
Based out of Ghengdu, China, Anticancer Bioscience is a medtech company with a focus on synthetic lethal approaches to precision oncology.Explore more
Anticancer Bioscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Anticancer Bioscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Anticancer Bioscience launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Anticancer Bioscience
Funding: Get notified immidiatlly once Anticancer Bioscience has new funding data
Click to see if Anticancer Bioscience had a recent Job posting/layoffs
Check out if Anticancer Bioscience is spiking on competitors!
Anticancer Bioscience, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Anticancer Bioscience has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Anticancer Bioscience recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Anticancer Bioscience
Find 2 more new buyers
Company Profile Activity
Activity Insights
Anticancer Bioscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Anticancer Bioscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Anticancer Bioscience.
Anticancer Bioscience financials insights
Gather financial insights about Anticancer Bioscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Other Financing Round
$10M
Angel/Seed
$31M
Anticancer Bioscience Tech Stack
A closer look at the technologies used by Anticancer Bioscience
See more technologies
Anticancer Bioscience News & Media
Anticancer Bioscience Raises Additional USD 10.6M; Closes Over $31M Seed Round
Anticancer Bioscience, a Chengdu, China-based developer of synthetic lethal approaches to precision oncology, secured an additional CNY 68.4m (~USD 10.6m) in seed extension financing. The round was led by Three Rivers Capital, who joined existing private Chinese investors. The total raised in the seed round is now over USD31m (around CNY 200m). The proceeds will […] The post Anticancer Bioscience Raises Additional USD 10.6M; Closes Over $31M Seed Round appeared first on FinSMEs.Anticancer Bioscience Welcomes New Investor into Seed Financing Round Bringing Total Raised to Over $31m to Advance Synthetic Lethality Approaches to Cancer Therapy
CHENGDU, China--(BUSINESS WIRE)-- #biotech--Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that it had secured an additional CNY 68.4 million (~USD 10.6 million) from new Chinese investors. The seed extension financing was led by Three Rivers Capital, who joins existing private Chinese investors. The total raised in the seed round is now over USD31 million (around CNY 200 million). The proceeds will be mainly used to accelerate the preAnticancer Bioscience Appoints Leader in Oncology Drug Development, Dr. Hong Liu, as US-based VP of Clinical Development
CHENGDU, China--(BUSINESS WIRE)-- #cancer--Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today appointment of Dr. Hong Liu as VP of Clinical Development. A physician-scientist, he will be based in Chengdu and San Francisco. ACB is commercializing inventions made in the J. Michael Bishop Institute of Cancer Research. In his earlier career Dr. Liu previously worked with Nobel laureate Dr. J. Michael Bishop at the University of California, SanAnticancer Bioscience Announces Preclinical Data of Lead Compounds Against Novel Myc Synthetic Lethal Target in Cancer
CHENGDU, China--(BUSINESS WIRE)-- #drugdiscovery--Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today progress in its MYC-synthetic lethal (MYC-SL) programme. The Company has identified three classes of novel small molecule compounds that demonstrate robust anti-cancer activity in preclinical studies, acting through interfering with mitosis and blocking cytokinesis. ACB is progressing through optimization and final candidate selection with
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anticancer Bioscience
Sign Up For FreeTo access detailed company insights
Based out of Ghengdu, China, Anticancer Bioscience is a medtech company with a focus on synthetic lethal approaches to precision oncology.... Read More
